PubMed Health⌕ Search

Biomedical subjects

F C Berthoux

Publications and source records attributed to F C Berthoux.

At least 55 records · Page 3Linked to original sources
PubMed1984

[Comparative evaluation of the function of each kidney using Tc 99m DTPA].

To evaluate the clinical validity of 99m Tc DTPA renal investigation, we have studied 60 patients with different renal diseases: 1) Renovascular hypertension (22 patients); 2) Chronic pyelonephritis (11 patients); 3) Renal hypoplasia (12 patients); 4) Bilateral parenchymatous nephropathy with hypertension (15 patients). We observed a good correlation between the creatinine clearance and the total DTPA clearance (N = 51: r = 0.68; p less than 0.001); and also a good correlation between the respective renal surface extrapolated from renal X-Rays, and the respective renal function of each kidney (expressed in percentage) measured from DTPA data. This correlation is higher in group 1 and lower in group 2. From individual kidney function percentage and glomerular filtration rate measurement or estimation, we could calculate the GFR of each kidney, which serves as a guideline for surgical decisions.

Adult↗
PubMed1983

[Treatment of accelerated arterial or malignant hypertension with captopril. Value, efficacy and outcome of visceral complications].

We have investigated 36 patients with accelerated or malignant hypertension (diastolic greater than 130 mm Hg and fundi at stage III or IV). The acute administration of Captopril 50 mg per os decreases the mean arterial pressure (MAP) by 20 p. cent during the 3 following hours. 30 patients have been treated from 1 to 9 months with Captopril (mean daily dose during first month = 212 mg) associated with Furosemide (mean daily dose = 80 mg) +/- beta blockers (11/30). The mean blood pressure in supine position under heavy conventional treatment was 205/121 mm Hg just before starting Captopril and was reduced to 156/90 mm Hg at the end of the first month of treatment. We observed a clear cut regression of fundi stages (III-IV to I-II) and cardiac or cerebral involvement, and a clearcut stabilization of the rapidly progressive chronic renal failure.

Adult↗
PubMed1983

Immunogenetics and immunopathology of human membranous glomerulonephritis.

In most of our membranous glomerulonephritis (MGN) patients, we have studied the HLA-A, B, DR phenotype, the clearance of anti-D rhesus coated 51Cr-labelled autologous erythrocytes, and T-lymphocyte subpopulations with monoclonal antibodies (OKT3, T4, T8). The frequency of B8 antigen in 28 patients with MGN (five cases associated with lupus excluded) is 57.14 per cent versus 14.42 per cent in controls (Pc = 0.0002). In 26 patients the frequency of DR3 antigen is 65.38 per cent versus 20.27 per cent in controls (Pc = 0.00008). The half-life of sensitised erythrocytes is respectively 35.36 +/- 8.50 minutes in nine controls and 67.05 +/- 69.64 min in 18 patients with MGN. The half-life is significantly prolonged in one-third of the patients at time of exacerbation. The peripheral blood T-lymphocyte subsets study showed a significant decrease of OKT3 and OKT4 positive cell subsets. T4/T8 ratio is high during exacerbation of disease and diminishes in remission. Our data are consistent with a latent subtle genetic immunodeficiency, only expressed during acute phases of the disease.

Antibodies, Monoclonal↗
PubMed1983

[Immunogenetics of intercapillary glomerulonephritis due to IgA deposits].

Idiopathic mesangial IgA nephritis (Berger's disease) and Schönlein-Henoch purpura mesangial IgA nephritis (SHP) have a common immunopathological pattern. There is a weak association with the MHC class I antigen, B35, which is a poor prognosis marker in Berger's disease and which predisposes to renal involvement in SHP. There is also an association with the MHC class II antigen, DR4, whose signification remains unclear. Many familial cases of Berger's disease have been reported in patients bearing the HLA-B35 antigen. We proposed that Berger's disease and SHP should be viewed as a unique entity according to their common immunogenetics and also common immunopathology.

Capillaries↗
PubMed1982

[Circulating immune complexes, detection in human glomerulonephritis by the PEG-EDTA technique (author's transl)].

In a prospective study, we screened sera samples of 128 patients with glomerulonephritis (GN) for the presence of circulating immune-complexes (CIC) fixing C1q by precipitation of native C1q with 2% polyethylene glycol (PEG) in the presence of 10 mM EDTA. The amount of precipitated C1q, as measured by Mancini, is less than 27% (m +/- 2 SD) of the original value in control sera. We found 35/128 (27%) positives samples, distributed as follows: 4/17 (24%) in acute GN, 10/15 (67%) in SLE, 2/16 (13%) in membraneous GN, 13/24 (54%) in membranoproliferative GN, 3/16 (19%) in segmental focal hyalinosis, 2/10 (20%) in minimal lesions nephrotic syndrome, and 1/30 (3%) in mesangial IgA GN. We then correlated these results with clinical, serological and pathological data. Whatever the type of GN, the presence of CIC fixing C1q correlated significantly, well with : the presence of chronic renal failure (serum creatinine greater than or equal to 2 mg/dl) (X2 = 5.48, p less than 0.02), the presence of hypocomplementemia (X2 = 12.30, p less than 0.001), the presence of low serum C3 (X2 = 8.25, p less than 0.01), the activation of C3 through normal pathway (low serum C4 and/or C1q) (X2 - 18.12, p less than 0.001) and the presence of glomerular deposits of C3 (X2 = 8.52, p less than 0.01), of C4 (X2 = 7.10, p less than 0.01), and of C1q (X2 = 4.11, p less than 0.05). The technique is simple, does not require labeled C1q, and allows the further study of antigen or antibody determinants of the complexes. Its sensitivity is near that of the 125 I-C1q binding assay technique. Such routine screening is a major immunopathologic step in the investigation of human GN.

Adult↗
PubMed1981

[Distal complications of therapeutic arteriovenous fistulae (author's transl)].

Having observed 4 personal cases, the authors review the distal complications of therapeutic arteriovenous fistulaes. Ischaemic complications are of arterial origin and may be severe: strong pain increasing during dialysis, soft tissue trophic disorders and ulcerations, and functional sequelae. Venous stasis disappear without permanent damage. The carpal tunnel syndrome is of uncertain and probably mixed aetiology and can easily be cured by surgical decompression. The use of small calibre, termino-terminal or latero-terminal distal anastomoses should help to prevent these complications.

Aged↗
PubMed1981

[Progression and severity of arterial hypertension in aged subjects (12 cases].

We analyzed retrospectively 12 patients, aged from 63 to 73 years, with renovascular hypertension due to unilateral or bilateral atheromatous lesions (4 out of 12). Malignant or accelerated hypertension with multiple visceral involvement was frequent (8 out of 12). The proximal lesions (stenosis) of the renal arteries were rapidly progressive, leading to complete thrombosis in 8 cases. Five patients received medical treatment only, but 2 worsened their GFR and 2 had a poor blood pressure control. Of the 5 patients who underwent renal surgery 2 had nephrectomy, 2 had an aorto-renal bypass and 1 a bypass plus nephrectomy; 2 of them recovered a normal GFR, but 2 died in the post-operative period. Three patients had selective embolization of a renal artery, but only one was definitely improved. So far, the treatment of such cases still is very difficult.

Aged↗
PubMed1980

Human glomerulonephritis and persistent non-polio enterovirus infection.

In a prospective work, we have studied the non-polio enterovirus (NPEV) excretion in spot urine and stools by four appropriate cell cultures, in four different groups: 20 exposed controls (GI), 88 patients with renal biopsy 'proven GN' (GII), 38 cases with 'proven nonGN' (GIII), and 9 with 'probable nonGN' (GIV). The positive excretion in stools and/or urine is respectively 0 and 5% in Group I, 14 and 33% in Group II, 6 and 19% in Group III, and 13 and 22% in Group IV. Viruria, the consequence of a viraemia, is therefore associated with 'proven GN' (p less than 0.05). In the majority of patients with positive NPEV excretion, we have made an additional but similar study, 3-12 months later. Persistent excretion was confirmed in 22/30 cases in Group II (73%) versus 0/8 in Group III-IV (p less than 0.001). These data concerned patients with membranoproliferative GN [5], membranous GN [6], mesangial IgA GN [6], endocapillary GN [2] or minimal lesions [3]. Thus we have demonstrated a significant relation between persistent NPEV urine/stools excretion and the occurrence of active GN in humans. Such persistent viral infections may represent the cause of some GN, probably mediated by an immune complex mechanism with viral antigens.

Enterovirus↗
PubMed1980

[Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].

C3 cleaving activity through alternate pathway, appreciated by native C3 antigen reduction in the presence of Mg EGTA, has been measured in sera of 40 controls and of 125 GN patients. The normal percentage of native C3 conversion ranged from 0 to 29 in controls (p less than 0.05). The number of positive samples is 0/30 in lupus GN (0%), 13/29 in acute GN (45%) and 26/66 in membranoproliferative GN (39%) with 7/8 in dense deposits subtype. The presence of alternate pathway activators of complement correlated with serum C3 level: their frequency is respectively 0, 0.32, and 0.48 if serum C3 is normal, low, and very low. Such activity correlated also well with alternate pathway C3 activation (low C3 and normal C4): the frequency of positive samples is respectively 0, 0.07, and 0.51 in the presence of No C3 activation, classical pathway activation (low C3 and low C4), and alternate pathway activation. The nature of such serum activators could be nephritic factor, bacterial polysaccharides, polymeric IgA, activated properdin, peculiar immune complexes, or other factors. Such measurement is an improvement immunopathological step in the investigation of human GN.

Complement Activation↗